Sign In
Buy AMRX
$18.09
+0.170 (+0.95%)
At Close: Jul 27, 2026
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of “Moderate Buy” from Analysts
03:16am, Thursday, 25'th Dec 2025
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five research firms that are covering the company, Marketbeat.com reports. One
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
04:01pm, Monday, 22'nd Dec 2025
BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial o
Assenagon Asset Management S.A. Raises Holdings in Amneal Pharmaceuticals, Inc. $AMRX
03:26am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) by 187.1% in the third quarter, according to the company in its most recent 13F filing with the Securit
Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks
11:01pm, Wednesday, 17'th Dec 2025
Today's article presents why Amneal should get my prior buy rating from September reaffirmed. Although some technical signals support a hold rather than bullishness, fundamental analysis shows several
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
04:01pm, Tuesday, 09'th Dec 2025
BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) ha
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson's Disease
08:00am, Friday, 05'th Dec 2025
BRIDGEWATER, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced new positive interim results from its ongoing Phase
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
08:00am, Tuesday, 02'nd Dec 2025
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) ha
Amneal to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 02'nd Dec 2025
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financi
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
04:01pm, Monday, 01'st Dec 2025
Approval underscores Amneal's advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026 BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWI
Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares?
05:49pm, Friday, 28'th Nov 2025
Westshore Wealth initiated 1,381,910 shares in Amneal Pharmaceuticals, a position value increase of $13.83 million. The transaction accounted for 4.73% of Westshore's 13F reportable assets under manag
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?
12:00pm, Friday, 28'th Nov 2025
ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival.
Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs
12:24pm, Friday, 21'st Nov 2025
The option-exercise sale represented a notable amount of Shah's overall holdings. Nevertheless, the executive's remaining stake—about 146,000 shares—still represents meaningful exposure.
Amneal Receives U.S. FDA Approval for Iohexol Injection
04:01pm, Thursday, 13'th Nov 2025
BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FDA) has app
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript
12:56pm, Thursday, 30'th Oct 2025
Amneal Pharmaceuticals, Inc. ( AMRX ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Anthony DiMeo - Head of Investor Relations Chirag Patel - Co-Founder, Co-CEO, President &
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
10:35am, Thursday, 30'th Oct 2025
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compar
